Milestone Scientific Schedules First Quarter 2026 Financial Results and Business Update Conference Call
Rhea-AI Summary
Milestone Scientific (NYSE: MLSS) will host a conference call at 8:30 AM ET on May 14, 2026 to discuss first-quarter 2026 financial results, corporate progress, and other developments. Dial-in numbers, access codes, a live webcast and replay are provided; the audio replay is available through May 28, 2026.
Webcast: https://www.webcaster5.com/Webcast/Page/2306/53997. U.S. dial-in: 888-506-0062; international: +1 973-528-0011; access code: 950491. Replay dial-in access code: 53997.
Positive
- None.
Negative
- None.
News Market Reaction – MLSS
In the May 8 session, MLSS declined 2.56%, reflecting a moderate negative market reaction. Argus tracked a peak move of +15.0% during that session. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | Earnings call scheduling | Neutral | -6.8% | Announced Q4 and full-year 2025 results conference call with webcast and replay. |
| Nov 13 | Earnings call scheduling | Neutral | +6.0% | Set Q3 2025 results call date, with dial-in details and webcast replay access. |
| Aug 13 | Earnings call scheduling | Neutral | -3.6% | Scheduled Q2 2025 results call to review performance and corporate developments. |
| Nov 12 | Earnings call scheduling | Neutral | +0.0% | Announced Q3 2024 results call with standard phone and webcast access options. |
| Aug 12 | Earnings call scheduling | Neutral | +5.2% | Outlined Q2 2024 results call, including access codes and replay availability. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Scheduling earnings calls has historically led to modest, mixed price moves, with both positive and negative reactions and an average change near flat.
Over the past several quarters, Milestone Scientific has repeatedly announced conference calls to discuss financial results and corporate progress, similar to this Q1 2026 scheduling. Past “conferences,earnings” notices on Mar 26, 2026, Nov 13, 2025, Aug 13, 2025, Nov 12, 2024, and Aug 12, 2024 produced mixed 24‑hour price reactions, ranging from declines to gains, but with an average move of about 0.18%, suggesting limited directional bias to this type of headline.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROSELAND, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced that it will host a conference call at 8:30 AM Eastern Time on Thursday, May 14, 2026, to discuss the company’s financial results for the first quarter ended March 31, 2026, as well as the company’s corporate progress and other developments.
The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 950491. A live webcast and replay are available here: https://www.webcaster5.com/Webcast/Page/2306/53997
An audio replay of the call will be available through May 28, 2026, and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and by entering the access code: 53997.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a technology-focused medical research and development company that patents, designs, and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2024. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason. Coding and payment decisions are determined solely by providers and payers based on applicable laws and policies. Any potential Category I designation is determined solely by the American Medical Association and is not guaranteed. Providers remain responsible for compliance with all applicable billing, coding, and regulatory requirements. Forward-looking case submission expectations, reimbursement targets, and revenue estimates referenced herein are based on current program enrollment, advisor commitments, and historical payer activity, and are subject to change based on clinical scheduling, payer processing timelines, regulatory developments, and other factors. There can be no assurance that Category I designation, targeted reimbursement levels, or projected revenue levels will be achieved.
Contact:
HAYDEN IR:
James Carbonara
(646)-755-7412
james@haydenir.com
Brett Maas
(646) 536-7331
brett@haydenir.com
